News

Mauna Kea Technologies Announces 2022 Nine Month Sales Results

27 October 2022

Global 9-month sales slightly down (5%) at €4.8 million while sales in the United States grew 23%

Mauna Kea Technologies today announced its sales results for the first nine months of 2022.

Sacha Loiseau, Ph.D., Chairman and Chief Executive Officer of Mauna Kea Technologies, commented: "Despite a challenging operating environment and the reallocation of resources associated with the strategic reorganization announced in late 2021, our commercial team has remained engaged and delivered satisfactory results, including 23% YTD growth in the United States.” Mr. Loiseau continued, “As I return to my executive leadership role, I am focused on improving the company's overall efficiency, capturing near-term growth opportunities and accelerating our development activities with strategic partners.”

​​​​For additional details and financial results, please see the full press release.

Latest News

Mauna Kea Technologies Announces Largest Annual Pancreatic Cyst Consortium at Digestive Disease Week® 2025 

Mauna Kea Technologies Announces Largest Annual Pancreatic Cyst Consortium at Digestive Disease Week® 2025 

Publication of the 2024 Annual Financial Report 

Publication of the 2024 Annual Financial Report 

Mauna Kea Technologies Announces Another Milestone Year at Digestive Disease Week® 2025 with 8 Presentations Demonstrating the Clinical Value of Cellvizio® in Key Indications 

Mauna Kea Technologies Announces Another Milestone Year at Digestive Disease Week® 2025 with 8 Presentations Demonstrating the Clinical Value of Cellvizio® in Key Indications 

No results found.